FDA Clearance Tracker · P990056-S007
ELECSYS TOTAL PSA IMMUNOASSAY AND ELECYS TOTAL PSA CALSET
Last checked: Nov 20, 2026Latest source record: Nov 18, 2008 (this decision)Source: openFDAMethods & limitations
Decided
Nov 18, 2008
Approved
Time to decision
454 days
Received Aug 22, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990056-S007
- Device name
- ELECSYS TOTAL PSA IMMUNOASSAY AND ELECYS TOTAL PSA CALSET
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Aug 22, 2007
- Decided
- Nov 18, 2008
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990056
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR EXTENSION OF THE ELECSYS TOTAL PSA AND CALSET II ONTO THE UPDATED MODEL OF THE ELECSYS 2010 ANALYZER, COBAS E 411 ANALYZER.
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.